• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

    10/6/25 10:13:00 AM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email

    Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients

    LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announced three Colorado-based events in October for healthcare professionals and community members to collaborate, learn, and advocate for lung health.

    First Event: October 9th APAPP Know Your Nodules Event at Biodesix Head Office in Louisville, CO

    The Association of Pulmonary Advanced Practice Providers (APAPP) Leadership and expert Faculty will run a half-day event: Know Your Nodules: Personalize. Prioritize. Prevent. APAPP Leadership will be hosting a clinician-centered lung disease and lung cancer screening / detection learning event at the Biodesix Corporate Headquarters in Louisville, Colorado. The event will also be live streamed. Faculty includes Corinne Young (President & Founder, APAPP), Stephen Deppen, PhD (Associate Professor of Thoracic Surgery and Epidemiology, Vanderbilt Medical Center), Rebecca Priebe (Acute Care Nurse Practitioner, Henry Ford Health), and Tammy Welch (Physician Assistant, Frederick Regional Health System).

    Second Event: October 9th – 11th Go2 for Lung Cancer Centers of Excellence Summit in Denver, CO

    The Go2 Association is hosting their annual Lung Cancer Centers of Excellence Summit in downtown Denver. This highly specialized educational event includes a full-day Lung Cancer Nurse Navigator module. Biodesix is a proud supporter of Go2 as they are driving to standardize best practices in lung nodule management at a national level. More details here.

    Third Event: October 12th American Lung Association in Colorado "Run the Rocks" at Red Rocks Amphitheater in Morrison, CO

    The American Lung Association in Colorado holds their annual Run the Rocks fundraiser and community awareness event at the world-renowned Red Rocks Amphitheater. The purpose of this event is to raise funds for education, research, and advocacy to save lives by improving lung health and preventing lung disease. More details here.

    "It is a privilege and honor to collaborate with these three partners here in our home state of Colorado. They each uniquely assist in our journey to achieve the Biodesix mission to conquer lung diseases through personalized diagnostics," said Scott Hutton, CEO at Biodesix. "I'd also like to note that these October events are well-timed as forerunners for November, which is Lung Cancer Awareness Month -- an important time of year for Biodesix advocacy and awareness efforts."

    About Biodesix:

    Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

    Biodesix Contacts:

    Media:

    Natalie St. Denis, Director Corporate Communications, Biodesix

    [email protected]

    (720) 925-9285

    Investors:

    Chris Brinzey, Partner, ICR

    [email protected]

    (339) 970-2843



    Primary Logo

    Get the next $BDSX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schuler Jack W bought $999,997 worth of shares (142,045 units at $7.04) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/23/25 9:29:04 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $111,425 worth of shares (18,373 units at $6.06) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/19/25 10:31:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $1,500,000 worth of shares (3,488,372 units at $0.43) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/3/25 4:42:40 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

    Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announced three Colorado-based events in October for healthcare professionals and community members to collaborate, learn, and advocate for lung health. First Event: October 9th APAPP Know Your Nodules Event at Biodesix Head Office in Louisville, CO The Association of Pulmonary Advanced Practice Providers (APAPP) Leadership and expert Faculty will run a half-day event: Know Your Nodules: Personalize. Prioritize. Prevent. APAPP Lead

    10/6/25 10:13:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces One-for-Twenty Reverse Stock Split

    LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company's common stock will continue to trade under Biodesix's existing trading symbol, BDSX, on the Nasdaq Global Market ("Nasdaq") on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207. The Reverse Stock Split was approved by Biodesix's stockholders at the a

    9/11/25 8:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference

    LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025. Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference Date: Thursday, September 11, 2025Location: New York, NY1x1 meetings only About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQ

    9/5/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman Patience John converted options into 1,144 shares, increasing direct ownership by 6% to 21,518 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    10/2/25 4:04:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $999,997 worth of shares (142,045 units at $7.04) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/23/25 9:29:04 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $111,425 worth of shares (18,373 units at $6.06) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/19/25 10:31:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    SEC Filings

    View All

    SEC Form 8-K filed by Biodesix Inc.

    8-K - BIODESIX INC (0001439725) (Filer)

    10/1/25 4:05:22 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

    SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

    9/23/25 9:29:31 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders

    8-K - BIODESIX INC (0001439725) (Filer)

    9/15/25 5:01:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces One-for-Twenty Reverse Stock Split

    LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company's common stock will continue to trade under Biodesix's existing trading symbol, BDSX, on the Nasdaq Global Market ("Nasdaq") on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207. The Reverse Stock Split was approved by Biodesix's stockholders at the a

    9/11/25 8:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Second Quarter 2025 Results and Highlights

    Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial

    8/7/25 4:06:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

    LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after t

    7/24/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care